165.21
-2.8 (-1.67%)
166.01
+0.8 (+0.48%)
We assign a fundamental rating of 2 out of 10 to PRAH. PRAH was compared to 57 industry peers in the Life Sciences Tools & Services industry. PRAH has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, PRAH is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
PRAH had positive earnings in the past year.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.98% | ||
| ROE | 13.71% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.03% | ||
| PM (TTM) | 6.4% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
There is no outstanding debt for PRAH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 3.56 indicates that PRAH is not in any danger for bankruptcy at the moment.
PRAH has a Debt/Equity ratio of 0.74. This is a neutral value indicating PRAH is somewhat dependend on debt financing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.56 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 1.21 indicates that PRAH should not have too much problems paying its short term obligations.
A Quick Ratio of 1.21 indicates that PRAH should not have too much problems paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.21 |
3. Growth
3.1 Past
The earnings per share for PRAH have decreased by -1.36% in the last year.
PRAH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 19.06% yearly.
The Revenue has been growing slightly by 6.57% in the past year.
The Revenue has been growing by 14.55% on average over the past years. This is quite good.
EPS 1Y (TTM)-1.36%
EPS 3Y12.65%
EPS 5Y19.06%
EPS Q2Q%28.57%
Revenue 1Y (TTM)6.57%
Revenue growth 3Y12.11%
Revenue growth 5Y14.55%
Sales Q2Q%19.15%
3.2 Future
PRAH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.49% yearly.
PRAH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.45% yearly.
EPS Next Y29.21%
EPS Next 2Y20.83%
EPS Next 3Y16.62%
EPS Next 5Y11.49%
Revenue Next Year19.32%
Revenue Next 2Y12.91%
Revenue Next 3Y11.31%
Revenue Next 5Y9.45%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 32.65 indicates a quite expensive valuation of PRAH.
PRAH's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 27.19.
With a Price/Forward Earnings ratio of 23.77, PRAH is valued on the expensive side.
PRAH is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.88, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.65 | ||
| Fwd PE | 23.77 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 23.96 |
4.3 Compensation for Growth
PRAH's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as PRAH's earnings are expected to grow with 16.62% in the coming years.
PEG (NY)1.12
PEG (5Y)1.71
EPS Next 2Y20.83%
EPS Next 3Y16.62%
5. Dividend
5.1 Amount
No dividends for PRAH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
165.21
-2.8 (-1.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner Change-99.98%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap10.70B
Revenue(TTM)3.33B
Net Income(TTM)213.32M
Analysts60
Price Target171.11 (3.57%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.65 | ||
| Fwd PE | 23.77 | ||
| P/S | 3.21 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.88 | ||
| P/tB | N/A | ||
| EV/EBITDA | 23.96 |
EPS(TTM)5.06
EY3.06%
EPS(NY)6.95
Fwd EY4.21%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS51.45
BVpS24.02
TBVpSN/A
PEG (NY)1.12
PEG (5Y)1.71
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.98% | ||
| ROE | 13.71% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 10.03% | ||
| PM (TTM) | 6.4% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.78
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.21 | ||
| Altman-Z | 3.56 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.36%
EPS 3Y12.65%
EPS 5Y19.06%
EPS Q2Q%28.57%
EPS Next Y29.21%
EPS Next 2Y20.83%
EPS Next 3Y16.62%
EPS Next 5Y11.49%
Revenue 1Y (TTM)6.57%
Revenue growth 3Y12.11%
Revenue growth 5Y14.55%
Sales Q2Q%19.15%
Revenue Next Year19.32%
Revenue Next 2Y12.91%
Revenue Next 3Y11.31%
Revenue Next 5Y9.45%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
Pra Health / PRAH FAQ
Can you provide the ChartMill fundamental rating for Pra Health?
ChartMill assigns a fundamental rating of 3 / 10 to PRAH.
What is the valuation status for PRAH stock?
ChartMill assigns a valuation rating of 4 / 10 to Pra Health (PRAH). This can be considered as Fairly Valued.
Can you provide the profitability details for Pra Health?
Pra Health (PRAH) has a profitability rating of 4 / 10.
Can you provide the financial health for PRAH stock?
The financial health rating of Pra Health (PRAH) is 3 / 10.
What is the earnings growth outlook for Pra Health?
The Earnings per Share (EPS) of Pra Health (PRAH) is expected to grow by 29.21% in the next year.